Cochrane · systematic review · CD008439
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection
Li, L, Tian, JH, Yang, K, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 14 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsPRO 140 compared to placebo for treatment of people with HIV infection
Population: patients being treated for HIV infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Antiviral response: 0.5 mg/kg PRO 140 vs placebo | OR 3 [0.11, 83.36] | 1 study · 19 participants | Very low Downgraded: risk of bias |
Antiviral response: 2 mg/kg PRO 140 vs placebo | OR 27.44 [1.25, 601.57] | 1 study · 19 participants | Very low Downgraded: risk of bias |
Antiviral response: 5 mg/kg PRO 140 vs placebo | OR 439.09 [25.73, 7493.14] | 2 studies · 40 participants | Very low Downgraded: risk of bias |
Antiviral response: 10 mg/kg PRO 140 vs placebo | OR 145.67 [5.3, 4004.91] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Antiviral response: 162 mg weekly PRO 140 vs placebo | OR 24.82 [1.17, 527.12] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Antiviral response: 324 mg weekly PRO 140 vs placebo | OR 147 [5.35, 4037.48] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Antiviral response: 324 mg biweekly PRO 140 vs placebo | OR 57 [2.59, 1253.22] | 1 study · 22 participants | Very low Downgraded: risk of bias |
PRO 140 compared to placebo for treatment of people with HIV infection
Population: patients being treated for HIV infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg PRO 140 vs placebo | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 2 mg/kg PRO 140 vs placebo | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 5 mg/kg PRO 140 vs placebo | no estimate extracted | 2 studies · 40 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 10 mg/kg PRO 140 vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 162 mg weekly PRO 140 vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 324 mg weekly PRO 140 vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias |
Individual nadir changes in HIV‐1 RNA level: 324 mg biweekly PRO 140 vs placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias |